Opinion|Videos|April 18, 2025
Future Directions for IL-17 Inhibitors in Psoriasis and Psoriatic Arthritis Care
Panelists discuss how medical professionals anticipate new IL-17 inhibitor data, particularly from head-to-head trials like BE BOLD. Interest is growing in sonelokimab, an IL-17A/F nanobody (Papp, 2021). Further research is needed on long-term efficacy, safety, and optimal patient selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What new data are you looking forward to seeing from the IL-17 inhibitor class in psoriasis?
- More head-to-head studies (BE BOLD)
- Sonelokimab—IL-17A/F nanobody (Papp, 2021)
- In your opinion, what research still needs to be done for this therapeutic class?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
The SkinCARE Questionnaire: Assessing the Psychological Dimensions of Skin Health Beyond Disease
5
